Clinical Trials · NCT00978211

DOTA-TOC in Metastasized Neuroendocrine Tumors

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
University Hospital, Basel, Switzerland
Enrollment
1,499
Start date
Sep 1997
Locations
1 site, Switzerland
Primary endpoint
Response
View Octreotide compound reference